Core Insights - Two international innovative drugs, Inclisiran sodium injection (new indication) and Ruxolitinib cream, have recently received approval for domestic market entry in China, supported by real-world data research from Hainan [2] Group 1: Drug Approvals - Inclisiran sodium injection is the world's first and only small interfering RNA drug targeting PCSK9 for cholesterol reduction, offering a "two injections a year" treatment plan for patients with hypercholesterolemia, which is expected to improve medication adherence and long-term lipid control rates [2] - Ruxolitinib cream is the first and only JAK inhibitor approved for localized treatment of vitiligo, which has already benefited nearly 10,000 patients since its emergency use approval in August 2023, filling a long-standing gap in targeted local therapies for this condition [2] Group 2: Market Impact - A total of 24 international innovative drugs and devices have been accelerated for domestic approval through this pathway, indicating a growing trend in the Chinese pharmaceutical market towards faster access to innovative treatments [2] - Ruxolitinib cream is advancing towards local registration in Hainan, with the potential for local production in Haikou National High-tech Zone by 2027, which could further benefit a larger patient population [2]

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and the fund's risk resistance by 2029 [2] Drug and Device Approvals - Zai Lab has received approval for clinical trials of injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [4] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [5] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the last 30 trading days [7] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [8] Industry Events - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the medical insurance catalog for 2025, with 6,537 being medical institutions and 4,592 retail pharmacies [10][11] - France has launched a roadmap to address national obesity issues, setting four key objectives to curb obesity growth and improve health outcomes [12] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for misleading statements in its restructuring plan, leading to a 20% drop in its stock price [14]

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and fund risk resistance by 2029 [1] Drug and Device Approvals - Zai Lab has received clinical trial approval for injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [2] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [3] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the previous 30 trading days [4] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [5] Industry Developments - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the 2025 medical insurance catalog, with 6,537 being medical institutions and 4,592 retail pharmacies [6][7] - France has launched a roadmap for addressing national obesity issues, with goals to curb obesity growth, improve health conditions, enhance accessibility to personalized medical services, and support innovative care methods from 2026 to 2030 [8] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for alleged misleading statements in its restructuring plan, leading to a 20% drop in its stock price [9]

Core Insights - The National Healthcare Security Administration (NHSA) is facilitating the implementation of negotiated drugs in the 2025 medical insurance catalog, providing a list of new negotiated drugs and innovative commercial insurance drugs for 2025 [1][2] Group 1: New Drug Distribution - As of January 11, 2026, 105 new negotiated drugs have been included in the medical insurance catalog, distributed across 11,129 designated medical institutions nationwide [1] - Among the 105 new negotiated drugs, 88 have available distribution information, with two drugs, namely Increlex and Liposomal Irinotecan, available in all 31 provinces and the Xinjiang Production and Construction Corps [1] - 20 drugs are available in more than 30 provinces, 53 drugs in more than 20 provinces, and 67 drugs in more than 10 provinces [1] Group 2: Commercial Insurance Drugs - There are 19 innovative commercial insurance drugs, with 16 having distribution information, and the drug Ipilimumab is available in over 30 provinces [1] - Seven commercial insurance drugs are distributed in more than 20 provinces, and 12 drugs are available in more than 10 provinces [1] Group 3: Monitoring and Compliance - The NHSA will focus on monitoring drugs that have not yet been distributed to designated medical institutions, ensuring that companies comply with distribution requirements to protect the medication rights of insured individuals [2]

Core Insights - The new basic medical insurance drug list has been officially implemented since January 1, 2026, with many insured individuals already purchasing newly added drugs from medical institutions [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the basic medical insurance drug list, with over half of these drugs already recorded in sales at medical institutions [1] - The drug Tirzepatide injection, used for treating adult type 2 diabetes, has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug Icosapent ethyl injection, which is administered once every six months, has been recorded in sales at 400 medical institutions [1] Group 2: Access and Information - Insured individuals can check the availability of insured drugs at medical institutions through the "National Medical Insurance Negotiated Drug Supply Institution List Inquiry" on the National Medical Insurance Service Platform [1]

Core Insights - The report emphasizes the importance of longevity medicine, which focuses on proactive health and disease prevention, as a critical response to the aging population and the challenges of "pathological longevity" [2][9][14] - The aging population in China is rapidly increasing, with the number of individuals aged 65 and above reaching 203 million in 2023, accounting for 25% of the global elderly population [10] - The demand for longevity medicine is accelerating, driven by the need for aging management, early prevention, and comprehensive health optimization, transitioning the healthcare model from disease treatment to continuous management [2][11][14] Industry Overview - The longevity medicine industry in China is still in its early stages, characterized by a dual-track development model where public institutions focus on research foundations while private entities explore service and business models [11] - The industry is facing structural pressures due to the increasing burden of chronic diseases and the inefficiencies of the traditional disease-centered healthcare system [2][10] - The report highlights that the core competitive advantage in the industry will shift towards long-term health management capabilities, data integration, and value proposition [11] Market Performance - The pharmaceutical sector showed positive performance in the week of January 5-9, 2026, with all six sub-sectors recording gains, particularly in medical services (+12.34%) and medical devices (+9.42%) [15] - The report notes that the valuation levels for biopharmaceuticals and chemical pharmaceuticals are among the highest, at 89.93 times and 84.19 times respectively [15] Innovations and Developments - A significant breakthrough in cancer vaccine research was reported by a team from Peking University, utilizing protein-targeted degradation technology to enhance immune response against cancer cells [22][25] - The new basic medical insurance drug list was implemented on January 1, 2026, with over half of the newly added 114 drugs already available in medical institutions [26] - The National Medical Products Administration is enhancing support for innovative drugs, aiming for a significant increase in the approval of new drugs and medical devices in 2025 [27][30][31]

Core Insights - The new basic medical insurance drug catalog has officially been implemented as of January 1, 2026, with 114 new drugs added [1] - Over half of the newly included drugs have recorded sales in medical institutions within the first week of implementation [1] Group 1: Drug Sales and Availability - The drug teriparatide injection for treating adult type 2 diabetes has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug inclisiran injection, known for its semi-annual dosing, has been sold in 400 medical institutions [1] Group 2: Access to Information - Insured individuals can check the availability of insurance-covered drugs in medical institutions through the National Medical Insurance Service Platform [1]

Core Insights - The new basic medical insurance drug list has been officially implemented since January 1, 2026, with many insured individuals already purchasing newly added drugs from medical institutions [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the basic medical insurance drug list, with over half of these drugs already recorded in sales at medical institutions [1] - The drug Tirzepatide injection, used for treating adult type 2 diabetes, has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug Icosapent ethyl injection, known for its "half-yearly injection" regimen, has been recorded in sales at 400 medical institutions [1] Group 2: Access and Information - Insured individuals can check the availability of insured drugs at medical institutions through the "National Medical Insurance Negotiated Drug Supply Institution List" on the National Medical Insurance Service Platform [1]

Core Viewpoint - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog, aimed at enhancing drug accessibility and supporting innovation in the pharmaceutical industry [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases like diabetes (12 drugs), anti-infective drugs (13 drugs), and rare diseases (10 drugs), while 29 drugs were removed due to better alternatives [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment reflects a comprehensive coverage of diseases, addressing clinical pain points and improving access to previously unavailable treatments for conditions like triple-negative breast cancer and pancreatic cancer [2]. Group 2: Policy Implementation and Access - To address the issue of new drugs being listed but not available in hospitals, the policy mandates that all designated medical institutions must include new drugs in their procurement catalogs by the end of February 2026, with provisions for temporary green channels if necessary [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one drug, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovative Drugs - Among the new drugs added to the basic medical insurance catalog, 50 are classified as category 1 innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The catalog includes both domestic innovative products and foreign original research products, enhancing the diversity of available treatments [4]. Group 4: Commercial Health Insurance Innovations - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that fill gaps in existing coverage, such as CAR-T cell therapies and treatments for rare diseases prevalent in children [7]. - This catalog complements the basic medical insurance, allowing pharmaceutical companies to expand their market reach while reducing the financial burden on patients [7]. Group 5: Industry Impact and Future Directions - The policy signals strong government support for independent innovation and encourages pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure effective implementation of the drug catalogs, ultimately improving the clinical medication needs of insured individuals [8].

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases (12 drugs), anti-infectives (13 drugs), and rare diseases (10 drugs) [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment aims to address clinical treatment gaps and enhance drug accessibility for patients, particularly for previously hard-to-treat conditions like triple-negative breast cancer and pancreatic cancer [2][4]. Group 2: Policy Implementation - A combination of policies will ensure that newly added drugs are available in hospitals by February 2026, including the establishment of temporary green channels for procurement [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one product, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovation - Among the new drugs, 50 are classified as first-class innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The inclusion of both domestic and foreign innovative products in the catalog reflects a commitment to enhancing drug accessibility and supporting pharmaceutical innovation [4]. Group 4: Commercial Health Insurance - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that complement the basic medical insurance offerings [7]. - The catalog features advanced therapies such as CAR-T cell treatments and drugs for rare diseases, which are expected to reduce patient financial burdens and enhance market attractiveness for pharmaceutical companies [7][8]. Group 5: Future Directions - The policy signals strong government support for independent innovation and aims to encourage pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Administration plans to refine policies and strengthen management to ensure the effective implementation of the drug catalogs, enhancing public access to necessary medications [8].